Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
1. Immix receives strategic investment from Goose Capital and Dr. Nancy T. Chang. 2. Dr. Chang has a history of developing successful FDA-approved therapies. 3. Goose Capital supports Immix's mission to commercialize NXC-201 for AL Amyloidosis. 4. NXC-201 shows promise in clinical trials and has regulatory designations. 5. Investment indicates strong confidence in Immix's future and market potential.